Combinatorial Targeted Therapy for Metastatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in effectively treating cancer at early or metastatic stages due to resistance issues and cumulative systemic side effects from oral or intravenous delivery of targeted drugs.
Innovation Solution
A combinatorial targeted therapy method that involves performing molecular diagnostics to detect genomic alterations at each cancer site, designing a combination targeted therapy, assigning drugs to systemic or local delivery based on their properties, and simultaneously delivering the drugs using a suitable delivery device, while monitoring progress and adjusting the therapy as needed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple targeted drugs are combined and administered simultaneously to block potential escape pathways, then the effectiveness against drug resistance is improved, but the systemic toxicity accumulates and causes serious side effects
Solution Approach 1:
The patent divides the cancer treatment into site-specific therapies, where each cancer site receives a customized combination of targeted drugs based on its unique genomic profile. This segmentation allows effective multi-drug combinations to be used locally at each site without the cumulative systemic toxicity that would result from administering all drugs systemically.
Solution Approach 2:
The patent implements local drug delivery through intratumoral injection, placing each targeted drug directly at the cancer site where it is needed. This local quality approach ensures high drug concentration at the tumor site while minimizing systemic exposure and toxicity, allowing aggressive combination therapies to be used safely.
2Measurement precision
If a different combination targeted therapy is used for each cancer site to address heterogeneous resistance mechanisms, then the treatment precision is improved, but the device complexity and treatment logistics become unmanageable
Solution Approach 1:
The patent segments the treatment process into discrete steps: molecular diagnostics for each site, personalized combination design for each site, and site-specific drug delivery. This segmentation makes the complex task of personalized multi-site treatment manageable by breaking it into standardized workflows that can be executed systematically.
Solution Approach 2:
The patent incorporates molecular diagnostics that provide feedback on the genomic alterations and resistance mechanisms at each cancer site. This feedback informs the selection and dosing of targeted drugs, allowing the treatment to be precisely tailored to each site's unique characteristics while maintaining overall treatment coordination.
3Object-affected harmful factors
If targeted therapy is used to kill only cancer cells with selective interference, then the side effects are reduced, but the cancer cells eventually develop resistance and the treatment becomes ineffective
Solution Approach 1:
The patent merges multiple targeted drugs with different mechanisms of action into site-specific combination therapies. By combining drugs that target different molecular pathways, the treatment achieves synergistic effects that prevent cancer cells from developing resistance through single pathway mutations, while maintaining the selective toxicity advantage of targeted therapy.
Solution Approach 2:
The patent performs molecular diagnostics before treatment to identify the specific genomic alterations and resistance mechanisms present at each cancer site. This preliminary action allows the selection of targeted drugs that will be effective against the patient's specific cancer profile, preventing resistance development from the outset rather than reacting to it afterward.
Data Source
AI summary
A combinatorial targeted therapy method for treating cancer, including metastatic cancer in a subject is provided, the method being designed to prevent unacceptable level of systemic toxicity in the subject and thus forced stoppage of the treatment, by performing initial molecular diagnostics to detect genomic alterations at each cancer site of the subject; for each cancer site, designing an initial combination targeted therapy by selecting a plurality of targeted drugs, based on the results of the initial molecular diagnostic at each cancer site; assigning each targeted drug to systemic or local delivery method, based on each targeted drug's properties; simultaneously treating all cancer sites according to the designed initial combination targeted therapy for each site, by delivering each targeted drug according to assigned delivery method to each targeted drug; and monitoring the progress of the cancer at each cancer site by performing follow-up molecular diagnostics at each cancer site.